A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)
GlaxoSmithKline
Summary
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
Eligibility
- Age range
- 18–70 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Capable of giving signed informed consent prior to the performance of any study-specific procedures. * Able and willing to comply with all study assessments and adhere to the protocol schedule of activities. * In the opinion of the investigator, there is a history of alcohol consumption compatible with either ALD or Met ALD. * A female participant is eligible to participate after meeting additional pre-defined criteria. * Participants must meet predefined stable use requirements of concomitant medications based on study criteria. * Participant has advanced chronic liver…
Interventions
- DrugGSK4532990
GSK4532990 will be administered
- DrugPlacebo
Placebo will be administered
Locations (131)
- GSK Investigational SiteChandler, Arizona
- GSK Investigational SitePhoenix, Arizona
- GSK Investigational SiteTucson, Arizona
- GSK Investigational SiteDavis, California
- GSK Investigational SiteLos Angeles, California
- GSK Investigational SiteLos Angeles, California